Drug Target Review

JUNE 19, 2024

The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. This provides some regulatory advantages, and of course, significant cost advantages.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Codon

FEBRUARY 13, 2024

By 2004, over a dozen companies were working on developing phage products and therapies, in locations ranging from Baltimore to Bangalore, where ten years previously, there had been none. Left) A molecular structure of bacteriophage T4, which infects E. And despite numerous high-profile, individual success stories in U.S.

Therapies 130

Therapies Virus DNA Clinical Trials 130

BMG Labtech

MARCH 8, 2023

DNA, proteins, polysaccharides, etc.). They are strongly oxidizing and, at high concentrations, are deleterious to cells damaging DNA, proteins and lipids, and eventually leading to cell death. Alberts B, How Cells Obtain Energy from Food, Molecular Biology of the Cell (4th ed.). nucleotides, monosaccharides, etc.),

Molecular Biology 52

Molecular Biology Production Cell Based Assays Disease 52

Codon

AUGUST 10, 2023

Journal of Molecular Biology (1961). Technologies DNA Sequencing →DNA sequencing at 40: past, present and future , by Shendure J. Link DNA Cost and Productivity Data, aka "Carlson Curves" , by Carlson R. Link Next-Generation DNA Sequencing Methods , by Mardis E.R. . & Xie X.S. Nature (2011).

DNA 98

DNA Cell Biology Molecular Biology Engineering 98

Codon

AUGUST 10, 2023

Journal of Molecular Biology (1961). Technologies DNA Sequencing →DNA sequencing at 40: past, present and future , by Shendure J. Link DNA Cost and Productivity Data, aka "Carlson Curves" , by Carlson R. Link Next-Generation DNA Sequencing Methods , by Mardis E.R. . & Xie X.S. Nature (2011).

DNA 52

DNA Cell Biology Engineering Molecular Biology 52